Clinical Trial Update: Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL [Phase 1]

View source ↗

Summary

A Phase 1 trial assessed the safety and tolerability of combining SGN-40 (dacetuzumab) with rituximab and gemcitabine in patients with diffuse large B-cell lymp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Rituximab (rituximab)
• SGN-40 (dacetuzumab)

Snippet

Sponsor: Seagen Inc. | Conditions: Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin | Phase 1 | Status: COMPLETED